Techsomed is a pioneering startup that operates in the medical technology sector, specifically in the field of Image Guided Ablation Therapy. The company has developed a unique image analysis system, BioTrace™, which is the first of its kind to predict and visualize the 24-hour post-treatment ablation morphology in real-time. This essentially means that it allows doctors to see the effects of a treatment on a patient's body in real-time, which was previously not possible.

The BioTrace™ system interfaces with commercial ultrasound imaging systems to track the tissue's unique "biological signature" when responding to heat during thermal ablation. This signature is then used to predict and visualize the post 24-hour thermal effect in real-time, enhancing the surgeon's control and accuracy during the procedure. This technology minimizes damage to healthy tissue and maximizes target tissue ablation, making treatments safer and more effective.

Techsomed's primary clients are healthcare providers and physicians who perform ablation therapies, particularly for oncology liver tumor ablation. The company's business model is based on selling its BioTrace™ system to these healthcare providers, thereby generating revenue.

In summary, Techsomed is a game-changer in the medical technology sector, transforming ablation treatments into guided precision therapies and advancing thermal ablation into the first line treatment option for tumor removal.

Keywords: Medical Technology, Image Guided Ablation Therapy, Real-Time Visualization, BioTrace™, Ultrasound Imaging, Biological Signature, Thermal Ablation, Oncology Liver Tumor Ablation, Healthcare Providers, Precision Therapies.